专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110300123A1 PHARMACOLOGICAL VITREOLYSIS 有权
标题翻译：药理学研究
公开(公告)号：US20110300123A1
公开(公告)日：2011-12-08
申请号：US13097985
申请日：2011-04-29
申请人： Steve PAKOLA , Marc DE SMET
发明人： Steve PAKOLA , Marc DE SMET
IPC分类号： A61K38/48 , A61P27/02
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
摘要翻译：治疗或预防受试者眼睛疾病或病症并发症的方法，包括使玻璃体和/或房水与包含纤维蛋白溶酶的催化结构域（TPCD）的截短形式的纤溶酶的组合物接触。 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。该方法可用于玻璃体切除术的缺失或辅助。

2. 发明授权

US07867489B2 Pharmacological vitreolysis 有权
标题翻译：药理性玻璃体解
公开(公告)号：US07867489B2
公开(公告)日：2011-01-11
申请号：US12156911
申请日：2008-06-05
申请人： Steve Pakola , Marc De Smet
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61K38/43 , A61M35/00
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
摘要翻译：治疗或预防受试者眼睛疾病或病症并发症的方法，包括使玻璃体和/或房水与包含纤维蛋白溶酶的催化结构域（TPCD）的截短形式的纤溶酶的组合物接触。 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。该方法可用于玻璃体切除术的缺失或辅助。

3. 发明申请

US20080050356A1 Pharmacological vitreolysis 有权
公开(公告)号：US20080050356A1
公开(公告)日：2008-02-28
申请号：US11786250
申请日：2007-04-11
申请人： Steve Pakola , Marc De Smet
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61K38/00 , A61P43/00
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

4. 发明授权

US07914783B2 Pharmacological vitreolysis 有权
标题翻译：药理性玻璃体解
公开(公告)号：US07914783B2
公开(公告)日：2011-03-29
申请号：US11786354
申请日：2007-04-11
申请人： Steve Pakola , Marc De Smet
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61K38/43 , A61K35/00
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
摘要翻译：包括使玻璃体和/或房水与包含纤溶酶（TPCD）的催化结构域的截短形式的纤溶酶的组合物接触的方法，所述方法包括使玻璃体和/或房室液体接触，披露 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。该方法可用于玻璃体切除术的缺失或辅助。

5. 发明申请

US20090074739A1 Pharmacological vitreolysis 有权
公开(公告)号：US20090074739A1
公开(公告)日：2009-03-19
申请号：US12156907
申请日：2008-06-05
申请人： Steve Pakola , Marc De Smet
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61P27/02
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

6. 发明申请

US20050118158A1 Pharmacological vitreolysis 有权
标题翻译：药理性玻璃体解
公开(公告)号：US20050118158A1
公开(公告)日：2005-06-02
申请号：US10729475
申请日：2003-12-05
申请人： Steve Pakola , Marc De Smet
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61K38/47
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
摘要翻译：治疗或预防受试者眼睛疾病或病症并发症的方法，包括使玻璃体和/或房水与包含纤维蛋白溶酶的催化结构域（TPCD）的截短形式的纤溶酶的组合物接触。 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。该方法可用于玻璃体切除术的缺失或辅助。

7. 发明授权

US08383105B2 Pharmacological vitreolysis 有权
公开(公告)号：US08383105B2
公开(公告)日：2013-02-26
申请号：US12951787
申请日：2010-11-22
申请人： Steve Pakola , Marc De Smet
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61K38/43 , A61M35/00
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

8. 发明授权

US07547435B2 Pharmacological vitreolysis 有权
标题翻译：药理性玻璃体解
公开(公告)号：US07547435B2
公开(公告)日：2009-06-16
申请号：US10729475
申请日：2003-12-05
申请人： Steve Pakola , Marc De Smet
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61K38/43 , A61M35/00
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
摘要翻译：包括使玻璃体和/或房水与包含纤溶酶（TPCD）的催化结构域的截短形式的纤溶酶的组合物接触的方法，所述方法包括使玻璃体和/或房室液体接触，披露 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。本发明的方法可用于降低玻璃体的粘度，使玻璃体液化，诱导玻璃体后脱离，减少眼睛出血，清除或减少对眼睛有毒的物质，清除或减少眼内异物增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。该方法可用于玻璃体切除术的缺失或辅助。

9. 发明申请

US20090081187A1 Pharmacological vitreolysis 有权
标题翻译：药理性玻璃体解
公开(公告)号：US20090081187A1
公开(公告)日：2009-03-26
申请号：US12156911
申请日：2008-06-05
申请人： Steve Pakola , Marc De Smet
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/48 , A61P27/02
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
摘要翻译：治疗或预防受试者眼睛疾病或病症并发症的方法，包括使玻璃体和/或房水与包含纤维蛋白溶酶的催化结构域（TPCD）的截短形式的纤溶酶的组合物接触。 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。该方法可用于玻璃体切除术的缺失或辅助。

10. 发明申请

US20080095753A1 Pharmacological vitreolysis 有权
标题翻译：药理性玻璃体解
公开(公告)号：US20080095753A1
公开(公告)日：2008-04-24
申请号：US11786354
申请日：2007-04-11
申请人： Steve Pakola , Marc De Smet
发明人： Steve Pakola , Marc De Smet
IPC分类号： A61K38/46 , A61P27/00
CPC分类号： A61K38/484 , A61K45/06 , C12Y302/01023 , C12Y302/01035 , C12Y304/21007 , C12Y304/24007 , C12Y402/02004 , C12Y402/02005 , C12Y402/02019 , A61K2300/00
摘要： Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
摘要翻译：包括使玻璃体和/或房水与包含纤溶酶（TPCD）的催化结构域的截短形式的纤溶酶的组合物接触的方法，所述方法包括使玻璃体和/或房室液体接触，披露 TPCD包括但不限于微型血小板，微量血浆及其衍生物和变体。本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。该方法可用于玻璃体切除术的缺失或辅助。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式